Rad-140 vs mk-677

RAD-140 recruits androgen receptor machinery in muscle and bone with tissue-selective agonism. MK-677 drives growth hormone secretion through ghrelin receptor activation in the pituitary. They belong to entirely different compound classes and generate growth through distinct pathways — which means the choice between them depends less on what you're trying to grow and more on which regulatory node you want to manipulate.

Quick Comparison

RAD-140: Androgen Receptor Agonism Without Full Virilization

RAD-140 (Testolone) binds the androgen receptor with high affinity — comparable to testosterone — but produces tissue-selective anabolic effects. In rodent models, this selectivity manifests as robust muscle and bone growth with reduced androgenic activity in prostate tissue. The mechanism involves conformational changes in the androgen receptor upon RAD-140 binding, which alter coactivator recruitment patterns and downstream gene transcription in a tissue-dependent manner.

Phase I human pharmacokinetic data showed dose-proportional increases in plasma concentration with oral administration, and the compound demonstrated acceptable safety at doses up to 150 mg daily over 28 days in healthy males. Testosterone suppression was observed at higher doses — predictable given the hypothalamic-pituitary-gonadal axis feedback — but no serious adverse events were reported. What remains absent is published Phase II efficacy data in human populations, which limits confidence in translating rodent muscle growth findings to clinical outcomes.

In vitro receptor binding studies confirm RAD-140's selectivity: it activates androgen receptor-mediated transcription in osteoblasts and myocytes while showing weaker activity in prostate epithelial cells compared to dihydrotestosterone. The exact structural basis for this selectivity is not fully characterized, but it likely involves differences in how the ligand-receptor complex interacts with tissue-specific coregulatory proteins.

MK-677: Sustained GH Secretion Through Ghrelin Mimicry

MK-677 operates by binding the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by endogenous ghrelin. This binding triggers pulsatile growth hormone release from anterior pituitary somatotrophs, which subsequently elevates insulin-like growth factor 1 (IGF-1) in circulation. The key advantage over exogenous growth hormone is preservation of the body's natural secretory rhythm and oral bioavailability.

Human trials in elderly populations showed sustained increases in serum GH and IGF-1 over months of daily dosing, with corresponding improvements in lean body mass and bone mineral density in some cohorts. A two-year randomized trial in 65 healthy elderly subjects demonstrated significant increases in fat-free mass but also notable side effects: increased appetite (expected, given ghrelin receptor agonism), transient edema, and elevated fasting glucose in a subset of participants. One case report linked MK-677 to drug-induced liver injury, though causality was not definitively established.

The pharmacodynamics are dose-dependent but not linear. Doses above 25 mg daily do not proportionally increase GH output, suggesting receptor saturation or negative feedback through IGF-1-mediated somatostatin release. The compound's half-life is relatively short, but GH elevations persist for 24 hours due to sustained receptor occupancy and secondary signaling cascades.

Where They Converge: Muscle Protein Synthesis Through Different Regulatory Nodes

Both compounds increase muscle protein synthesis, but through non-overlapping pathways. RAD-140 directly activates androgen receptor signaling in myocytes, upregulating genes involved in ribosomal biogenesis and mTOR pathway activation. MK-677 drives IGF-1 elevation, which activates PI3K/Akt/mTOR signaling independent of androgen receptor involvement. In rodent combination studies, simultaneous use produced additive lean mass gains greater than either compound alone — consistent with mechanistic independence.

The bone effects also differ mechanistically. RAD-140 increases osteoblast activity through androgen receptor-mediated transcription of bone matrix proteins. MK-677 influences bone remodeling through IGF-1 stimulation of both osteoblasts and chondrocytes, with secondary effects on calcium retention and bone mineral density. Neither compound shows significant anti-resorptive activity, meaning they build new bone but do not directly inhibit osteoclast-mediated breakdown.

Neither compound aromatizes to estrogen. RAD-140 avoids aromatization because it is not a substrate for aromatase enzyme. MK-677 does not interact with steroid metabolism at all. This eliminates estrogen-mediated side effects common to exogenous testosterone but also removes the beneficial effects of estrogen on lipid profiles and cognitive function.

The Practical Research Decision: Evidence Quality and Regulatory Axis Choice

If the research question involves androgen receptor function — either muscle-specific anabolic signaling or neuroprotective effects in dopaminergic neurons (demonstrated in rodent Parkinson's models) — RAD-140 is the appropriate tool. Its mechanism is direct, its receptor target is well-characterized, and the absence of Phase II human data is less limiting if the question is mechanistic rather than clinical. The compound's oral bioavailability and half-life make single daily dosing feasible in controlled studies.

If the research involves growth hormone axis manipulation — IGF-1-mediated effects on aging, sarcopenia, or metabolic regulation — MK-677 is the correct choice. It has been studied in human populations over extended periods, which provides better safety and efficacy baselines than RAD-140. The appetite stimulation is a limitation if body composition is the endpoint, but it is a feature if the research involves cachexia or anorexia of aging. The glucose metabolism effects require monitoring; insulin resistance is a documented concern in long-term use.

Combining them is mechanistically sound for additive anabolic effects but introduces complexity in interpreting results. For research purposes only, stacking requires accounting for two distinct suppressive mechanisms: RAD-140 suppresses endogenous testosterone through hypothalamic feedback, while MK-677 may reduce endogenous GH pulsatility through chronic IGF-1 elevation. Neither effect is catastrophic in short-term research contexts, but both require post-study normalization periods.

The evidence quality gap favors MK-677 for translational research. Multiple published Phase II trials provide human dosing data, adverse event profiles, and efficacy benchmarks. RAD-140's Phase I data confirm safety at low doses but offer no efficacy signals in humans. If the goal is hypothesis generation for later clinical work, MK-677's human data provides a clearer path. If the goal is mechanistic dissection of androgen receptor signaling independent of clinical validation, RAD-140 remains useful despite the evidence gap.

FAQ

Q: Can RAD-140 and MK-677 be used together in research models?

Yes, and rodent studies suggest additive effects on lean mass gain. The mechanisms do not overlap — androgen receptor agonism is independent of GH/IGF-1 axis stimulation — so there is no redundancy. The practical consideration is monitoring for compounded suppression of endogenous hormone production: RAD-140 suppresses gonadotropins, MK-677 may blunt natural GH pulsatility. Both effects are reversible but require washout planning.

Q: Does MK-677 require post-cycle normalization like RAD-140?

MK-677 does not suppress testosterone, so it does not require testosterone restoration protocols. However, chronic GH elevation may alter insulin sensitivity and glucose metabolism, effects that normalize over weeks after cessation. RAD-140 suppresses testosterone in a dose-dependent manner, requiring monitoring and potential normalization depending on study duration and endpoints.

Q: Which compound has better-documented human safety data?

MK-677, unambiguously. It has been studied in Phase II trials lasting up to two years, with documented adverse events including appetite increase, fluid retention, and glucose dysregulation. RAD-140 has Phase I safety data in healthy males up to 28 days but no long-term human studies. One case of hepatotoxicity has been reported with MK-677 use, though causality was not definitively established.

Q: Do either of these compounds affect estrogen levels?

Neither compound aromatizes to estrogen. RAD-140 is not a substrate for aromatase enzyme. MK-677 does not interact with steroid hormone pathways. This eliminates estrogen-mediated gynecomastia risk but also removes estrogen's beneficial effects on lipid metabolism and bone resorption.

Q: How do their half-lives affect dosing strategies in research?

RAD-140's 16-20 hour half-life supports once-daily dosing with stable plasma concentrations. MK-677's shorter half-life still produces 24-hour GH elevation due to sustained receptor activation, making once-daily dosing effective despite rapid plasma clearance. Split dosing offers no clear mechanistic advantage for either compound in most research contexts.

---

This article is for educational and informational purposes only. RAD-140 and MK-677 are not approved for human use by the FDA and should only be used in controlled research settings. Consult appropriate regulatory guidance before initiating any study involving these compounds.